Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001528-41
    Sponsor's Protocol Code Number:PG324-CS303
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-05-25
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-001528-41
    A.3Full title of the trial
    A prospective, double-masked, randomized, multicenter, active-controlled,
    parallel-group, 6-month study assessing the safety and ocular hypotensive
    efficacy of PG324 Ophthalmic Solution compared to GANFORT®
    (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with
    elevated intraocular pressure (MERCURY 3)
    Studio prospettico, in doppio cieco, randomizzato, multicentrico, con controllo attivo, a gruppi paralleli, della durata di 6 mesi volto a valutare la sicurezza e l'efficacia ipotensiva oculare di PG324 soluzione oftalmica, rispetto a GANFORT® (bimatoprost 0,03%/timololo 0,5%) soluzione oftalmica, in soggetti con pressione intraoculare elevata (MERCURY 3)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A prospective, double-masked, randomized, multicenter, active-controlled,
    parallel-group, 6-month study assessing the safety and ocular hypotensive
    efficacy of PG324 Ophthalmic Solution compared to GANFORT®
    (bimatoprost 0.03% / timolol 0.5% Opthalmic Solution) in subjects with
    elevated intraocular pressure (MERCURY 3)
    Studio prospettico, in doppio cieco, randomizzato, multicentrico, con controllo attivo, a gruppi paralleli, della durata di 6 mesi volto a valutare la sicurezza e l'efficacia ipotensiva oculare di PG324 soluzione oftalmica, rispetto a GANFORT® (bimatoprost 0,03%/timololo 0,5%) soluzione oftalmica, in soggetti con pressione intraoculare elevata (MERCURY 3)
    A.3.2Name or abbreviated title of the trial where available
    MERCURY 3
    MERCURY 3
    A.4.1Sponsor's protocol code numberPG324-CS303
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAERIE PHARMACEUTICALS IRELAND LTD.
    B.1.3.4CountryIreland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAerie Pharmaceuticals Ireland Ltd.
    B.4.2CountryIreland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAerie Pharmaceuticals Ireland Ltd.
    B.5.2Functional name of contact pointFinbar O'Neill
    B.5.3 Address:
    B.5.3.1Street AddressPembroke House , 28-32 Pembroke Street Upper
    B.5.3.2Town/ cityDublin 2
    B.5.3.3Post codeD02EK84
    B.5.3.4CountryIreland
    B.5.4Telephone number+353876328837
    B.5.5Fax number00000000
    B.5.6E-mailMercury3@aeriepharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRoclatan
    D.3.2Product code [PG324]
    D.3.4Pharmaceutical form Eye drops, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPTopical use (Noncurrent)
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INN00175500
    D.3.9.1CAS number 130209-82-4
    D.3.9.2Current sponsor codePG324
    D.3.9.3Other descriptive nameLATANOPROST
    D.3.9.4EV Substance CodeSUB08409MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg/µl microgram(s)/microlitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNetarsudil
    D.3.9.1CAS number 1422144-42-0
    D.3.9.2Current sponsor codeAR-13324
    D.3.9.4EV Substance CodeSUB186855
    D.3.10 Strength
    D.3.10.1Concentration unit % (W/V) percent weight/volume
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name GANFORT®
    D.2.1.1.2Name of the Marketing Authorisation holderAllergan Pharmaceuticals Ireland Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGANFORT®
    D.3.2Product code [GANFORT®]
    D.3.4Pharmaceutical form Eye drops, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPTopical use (Noncurrent)
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INN00047000
    D.3.9.1CAS number 155206-00-1
    D.3.9.2Current sponsor coden/a
    D.3.9.3Other descriptive namen/a
    D.3.9.4EV Substance CodeSUB12470MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg/µl microgram(s)/microlitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number300
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTIMOLOL
    D.3.9.1CAS number 26839-75-8
    D.3.9.2Current sponsor coden/a
    D.3.9.3Other descriptive namen/a
    D.3.9.4EV Substance CodeSUB11069MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    open angle glaucoma (OAG) or ocular hypertension (OHT)
    glaucoma ad angolo aperto (GAA) o ipertensione oculare (OHT)
    E.1.1.1Medical condition in easily understood language
    open angle glaucoma (OAG) or ocular hypertension (OHT)
    glaucoma ad angolo aperto (GAA) o ipertensione oculare (OHT)
    E.1.1.2Therapeutic area Diseases [C] - Eye Diseases [C11]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10043273
    E.1.2Term Tension ocular increased
    E.1.2System Organ Class 100000004848
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate:
    The ocular hypotensive efficacy of PG324 Ophthalmic Solution relative to GANFORT® Ophthalmic Solution at 08,00,10:00 and 16:00 hours at Week 2, Week 6 and Month 3.
    Valutare:
    L'efficacia ipotensiva oculare di PG324 soluzione oftalmica rispetto a GANFORT® Soluzione Oftalmica alle 8:00, alle 10:00 e alle 16:00 della Settimana 2,della Settimana 6 e del Mese 3.
    E.2.2Secondary objectives of the trial
    To evaluate:
    • The ocular and systemic safety of PG324 Ophthalmic Solution relative to GANFORT® Ophthalmic solution over a 6-month period
    • Change in Self-Administered National Eye Institute ( NEI) Visual Functioning Questionnaire 25 (VFQ-25) score from baseline to study exit for PG324 compared to GANFORT®
    • Change in self-administered Short Form Health Survey Questionnaire 36 (SF-36 v2) score from baseline to study exit for PG324 compared to GANFORT®
    Valutare:
    • L'efficacia oculare e sistemica di PG324 soluzione oftalmica rispetto a GANFORT® soluzione oftalmica per un periodo di 6 mesi.
    • Valutare le variazioni del punteggio per il Questionario a 25 domande sulla funzione visiva del National Eye Institute (NEI) auto-somministrato (VFQ 25) dal basale all'uscita dallo studio per PG324 rispetto a GANFORT®.
    • Valutare le variazioni del punteggio per il Questionario breve a 36 domande auto-somministrato sullo stato di salute (SF-36 v2), dal basale all’uscita dallo studio per PG324 rispetto a GANFORT®.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects have to meet all of the following criteria at screening and qualification visits to enter into the study:
    1. Must be 18 years of age or older
    2. Diagnosis of OAG or OHT in both eyes (OAG in one eye and OHT in the fellow eye is acceptable)
    3. Subjects insufficiently controlled and/or subjects considered in need for combination therapy by the investigators
    4. Medicated intraocular pressure = 17mmHg in at least one eye and < 28mmHg in both eyes at the screening
    5. Unmedicated (post-washout) IOP > 20mmHg in at least one eye and < 36mmHg in both eyes at 2 qualification visits at 08:00 hour, 2-7 days apart. At the second qualification visit, have IOP > 17mmHg in at least one eye and < 36mmHg in both eyes at 10:00 and 16:00 hours.
    Note: For purposes of determining eligibility of subjects to be enrolled the non–integral IOP mean number will be used. Any non-integral mean IOP number should not be rounded. If only one eye qualifies at the second qualification visit it MUST be the same eye that qualified on the first visit and this will be the
    study eye for the duration of the study.
    6. Best corrected visual acuity +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200 or better Snellen visual acuity in each eye)
    7. Be able and willing to give signed informed consent and follow study instructions
    8. Women must be either of non-child bearing potential, or women with child bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study
    9. Women of child bearing potential must have a negative urine pregnancy test within 7 days of first dose of study treatment and agree to use highly effective contraception during the study and for 3 months after the last dose of study medication
    10. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective form of contraception from time of randomization and for 3months following the last dose of study medication.
    11. In France, a subject will be eligible for inclusion in this study only if either affiliated to or as a beneficiary of a social security number
    Per poter partecipare allo studio, i soggetti devono soddisfare tutti i seguenti criteri allo Screening e alle Visite di Qualificazione:

    1. Avere un'età pari o superiore a 18 anni.
    2. Aver ricevuto una diagnosi di GAA od OHT per entrambi gli occhi (è accettabile GAA in un occhio e OHT nell'altro occhio).
    3. Soggetti controllati in modo insufficiente e/o soggetti che il/gli sperimentatore/i considerino abbiano bisogno di una terapia di combinazione.
    4. Pressione intraoculare trattata =17mmHg in almeno un occhio e <28mmHg in entrambi gli occhi in occasione della Visita di Screening
    5. IOP non trattata (post-washout) >20mmHg in almeno un occhio e <36mmHg in entrambi gli occhi in occasione delle due Visite di Qualificazione alle 08:00, 2-7 giorni di distanza. Alla Visita di Qualificazione 2, presentare una IOP >17mmHg in almeno un occhio e <36mmHg in entrambi gli occhi alle 10:00 e alle 16:00. Nota: Allo scopo di determinare l'idoneità dei soggetti da arruolare si utilizzerà la media non integrale della IOP. Qualunque valore della media non integrale di IOP non deve essere arrotondato. Se solo un occhio risulta idoneo alla Visita di Qualificazione 2, questo DEVE essere lo stesso occhio che è risultato idoneo alla prima visita e sarà l’occhio dello studio per la durata dello studio.
    6. Migliore acuità visiva corretta di +1,0 logMAR o superiore mediante la tavola ETDRS in ciascun occhio (equivalente a 20/200 o migliore di acuità visiva (Snellen) in ciascun occhio).
    7. Essere in grado e disposto/a a firmare il consenso informato e seguire le istruzioni dello studio.
    8. Le donne devono non essere in età fertile oppure devono essere donne in età fertile e uomini con potenziale riproduttivo disponibili ad utilizzare metodi di contraccezione adeguati durante lo studio.
    9. Le donne in età fertile devono avere un test di gravidanza (urine) negativo nei 7 giorni successivi all'assunzione della prima dose del trattamento dello studio e devono accettare di utilizzare dei metodi contraccettivi altamente efficaci durante lo studio e per i 3 mesi successivi all'assunzione dell'ultima dose del farmaco dello studio.
    10. Gli uomini le cui compagne sono in età fertile devono essere stati sottoposti precedentemente a vasectomia o devono accettare di utilizzare dei metodi contraccettivi efficaci dal momento in cui vengono randomizzati e per i 3 mesi successivi all'assunzione dell'ultima dose del farmaco dello studio.
    11. In Francia un soggetto potrà essere incluso in questo studio solo se possiede un numero di previdenza sociale o se ne è beneficiario.
    E.4Principal exclusion criteria
    Ophthalmic:
    1. Clinically significant ocular disease which might interfere with interpretation of the study efficacy endpoints or with safety assessments,including subjects with glaucomatous damage so severe that washout of ocular hypotensive medications for 4 weeks or longer if needed is not judged safe as it would put the subject at risk for further vision loss.
    2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable
    3.Intraocular pressure = 36mmHg (unmedicated) in either eye, or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combination medications, for the purpose of this exclusion criterion, count as one medication. However, subjects currently taking 2 fixed dose combination products are excluded.
    4. Treatment-naïve subjects
    5. Prior treatment with GANFORT® topical eye drops where the subjects IOP did not achieve the target IOP
    and was considered either a therapeutic failure or to have insufficient response. Subjects currently
    being treated with GANFORT® are excluded from the study.
    6. Known hypersensitivity to any component of the investigational formulations to be used or to fluorescein
    7. Previous glaucoma intraocular surgery, including SLT or ALT in either eye.
    8. Refractive surgery in either eye
    9. Ocular trauma within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening
    10. Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, keratitis, current evidence or history of herpes simplex or zoster keratitis in either eye at screening
    11. Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study, with the exception of a) ocular hypotensive medications which must have been the same medication for 30 days prior to screening, b) lid scrubs, c) lubricating drops for dry eye as prescribed by the Investigator.
    12. Mean central corneal thickness greater than 620µm at screening
    13. Any abnormality preventing reliable Goldmann applanation tonometry of either eye Systemic:
    14. Clinically significant abnormalities in laboratory tests at screening
    15. Known hypersensitivity or contraindication to GANFORT® and to ß-adrenoceptor antagonists.
    16. Clinically significant systemic disease which might interfere with the study
    17. Participation in any investigational study within 30 days prior to screening
    18. Systemic medication including corticosteroid containing drugs that could have a substantial effect on IOP which HAVE NOT been maintained at a consistent dose and regime within 30 days prior to screening and are anticipated to change in dose and/or regimen during the study.
    19. Use of topical steroid containing medications on the face or in or around the eyes will exclude the subject.
    20. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable and highly effective form of birth control. An adult woman is considered to be of
    childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization.
    21. Vulnerable subjects such as minors, adults under legal protection or unable to express their consent, persons deprived of liberty, or persons subject to psychiatric care.
    Oftalmici:1.Pat oc significat da pdv clinico, che potrebbe interferire con l'interpretaz degli endpoint di efficacia dello studio o con le valutaz di sicurez; sono compresi anche i sogg con danno glaucomatoso così grave che il washout dai farm ipoten oculari per 4 sett o più, se necessario, è giudicato nn sicuro dal momento che esporrebbe il sogg al rischio di un'ulteriore perdita della visione. 2. Glaucoma pseudoesfoliativo o glaucoma con dispersione di pigmento, eventi pregr.i di glaucoma ad ang chiuso o ad ang stretto. Nota: Una iridotomia periferica mediante laser NON è accettab.3. Una pressione intraoculare =36mmHg (non trattata) in entrambi gli occhi o uso di più di due farm ipotensivi oculari nei 30 gg dello Screen. Nota: i farm in combinazione a dose fissa vengano conteggiati come un unico farm ai fini di questo criterio di es. Tuttavia, sono esclusi i sogg che assumono al momento 2 farm in comb a dose fissa.4. Sogg. naïve al trattam. 5. Trat precedente con GANFORT® collirio ad uso topico, nel caso in cui l’IOP del sogg non raggiunga il valore target della IOP e ciò sia considerato o un fallimento terap o una risp insuff. I sogg, che al momento sono trattati con GANFORT®, sono esclusi dallo studio. 6. Ipersensibilità nota a qualsiasi componente delle form in speriment. da usare o alla fluoresceina 7.Preced operazione chirur intraoc del glaucoma, tra cui la trabeculoplastica con laser selettiva (SLT) e ad argon (ALT) in entrambi gli occhi. 8. Intervento di chirurg. refrattiva in entrambi gli occhi 9. Trauma ocu nei 6 mesi preced. lo Screen. o intervento chir ocu o trattam. laser non di carattere refrattivo nei 3 mesi precedenti lo Screen.10.Evidenza recente o attuale di infezione o infiamm oculare in entrambi gli occhi. Evidenza attuale di blefarite, congiuntivite, cheratite significative da un pdv clinico, evidenza attuale o eventi pregressi di cheratite da herpes simplex o zoster in entrambi gli occhi allo Screen.11.uso di farm oftalmici in entrambi gli occhi e di qualunque tipo nei 30 gg di Screen e durante lo studio, con l'eccezione di a) farm ipotensivi oculari, che devono essere sempre gli stessi negli ultimi 30 gg prima dello Screen, b) scrub palpebrali c) gocce lubrificanti per gli occhi secchi, come stabilito dal PI.12. Spessore corneale medio al centro sup. a 620µm allo Screen 13. Qualunque anomalia che prevenga una tonometria ad applanazione con tonometro di Goldmann affidabile di entrambi gli occhi Sistemici:14. Anomalie signific. da un pdv clinico negli esami di laboratorio allo Screen.15. Ipersensibilità nota o controin per GANFORT® e per gli antagonisti del recettore ß-adrenergico. 16. Patologia sist signific. da un pdv clinico che potrebbe interferire con lo studio.17. Partecipaz. a qualunque altro studio sper nei 30 gg precedenti lo Screen. 18.Assunzione di un farm sistemico, compresi i farm che contengono corticosteroidi, che potrebbe avere un effetto sostanziale sulla IOP che NON è stato mantenuto a una dose e un regime costanti nei 30 gg precedenti lo Screen, e la cui modifica della dose e/o del regime sia prevista durante lo studio. 19.Uso di medicinali contenenti steroidi topici sul viso o attorno agli occhi escluderà i sogg dallo studio. 20.Donne in età fertile che sono in grav, allatt o che stanno pianificando una grav oppure che non utilizzano una forma contraccettiva accettabile da un pdv medico e che sia altamente efficace. Una donna adulta viene considerata "in età fertile" a meno che non sia in post-menopausa da 1 anno oppure non abbia subito da 3 mesi un un intervento chirur di sterilizzazione 21.Sogg “vulnerabili”, quali minori. adulti sottoposti a tutela legale o sogg non in grado di esprimere il proprio consenso, persone prive di libertà o sogg sottoposti a cure psichiatriche
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy outcome will be comparison of PG324 Ophthalmic
    Solution relative to GANFORT® for:
    • Mean IOP within a treatment group at the following time points:
    08:00, 10:00, and 16:00 hours at the Week 2, Week 6, and Month 3 study
    visits
    L'outcome primario di efficacia sarà il confronto di PG324 soluzione oftalmica rispetto a GANFORT® per:
    • IOP media in un gruppo di trattamento nei seguenti momenti: alle 08:00, alle 10:00 e alle 16:00 alle visite dello studio della Settimana 2, Settimana 6 e Mese 3.
    E.5.1.1Timepoint(s) of evaluation of this end point
    end of last dose treatment and at the end of clinical trial
    fine dell'ultima dose di trattamento e alla fine dello studio clinico
    E.5.2Secondary end point(s)
    Secondary efficacy outcomes will be comparison of PG324 Ophthalmic
    Solution relative to GANFORT® for:
    • Mean diurnal IOP within a treatment group at each post-treatment
    visit.
    • Mean change from diurnally adjusted baseline IOP at each posttreatment
    time point.
    • Mean change from baseline in diurnal IOP at each post-treatment visit.
    • Mean percent change from diurnally adjusted baseline IOP at each
    post-treatment time point.
    • Mean percent change from baseline in diurnal IOP at each posttreatment
    visit.
    • Percentages of subjects achieving pre-specified mean, mean change,
    and percent mean change in diurnal IOP levels.
    L'outcome secondario di efficacia sarà il confronto di PG324 soluzione oftalmica rispetto a GANFORT® per: • IOP media diurna in un gruppo di trattamento in occasione di ciascuna visita post-trattamento. • Variazione media dalla IOP al basale aggiustata durante il giorno in occasione di ciascun momento post-trattamento. • Variazione media dal basale della IOP diurna in occasione di ciascuna visita post-trattamento. • Variazione percentuale media dalla IOP del basale aggiustata durante il giorno in occasione di ciascun momento post-trattamento. • Variazione percentuale media dal basale della IOP diurna in occasione di ciascuna visita post-trattamento. • Percentuale di soggetti che raggiungono la media, la variazione media e la variazione percentuale media dei valori di IOP diurna specificati in anticipo. • Percentuali di soggetti che raggiungono la media pre-specificata, il cambiamento medio e la variazione media delle percentuali nei livelli di IOP diurni
    E.5.2.1Timepoint(s) of evaluation of this end point
    End of last dose treatment and at the end of clinical trial.
    Trattamento alla fine dell'ultima dose e alla fine della sperimentazione clinica.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis Yes
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA71
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study when the last visit of the last subject has completed at the last site of all the countries taking part in the study
    La fine dello studio è prevista quando l'ultima visita dell'ultimo soggetto è stata completata nell'ultimo centro tra tutti i paesi che hanno preso parte allo studio
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days15
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days15
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 157
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 279
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state135
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 440
    F.4.2.2In the whole clinical trial 440
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the end of the study, the study drug will not be available so patients
    that participated in this trial will need other therapy based from the
    patient physician recommendation that is offered in the market.
    Alla fine dello studio, il farmaco di studio non sarà disponibile perciò i pazienti che hanno partecipato a questo studio necessiteranno di un'altra terapia, su raccomandazione del medico del paziente, che è disponibile sul mercato.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-01-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-07-18
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:27:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA